Acasti Pharma, Inc. - (ACST): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACST Stock Price Chart Interactive Chart >
ACST Price/Volume Stats
|Current price||$0.50||52-week high||$1.22|
|Prev. close||$0.53||52-week low||$0.17|
|Day high||$0.53||Avg. volume||28,372,254|
|50-day MA||$0.49||Dividend yield||N/A|
|200-day MA||$0.46||Market Cap||105.21M|
Acasti Pharma, Inc. - (ACST) Company Bio
Acasti Pharma Inc operates as pharmaceutical company. The Company develops drugs for cardiovascular diseases. Acasti offers omega-3 phospholipids a major component of cell membranes.
ACST Latest News Stream
|Loading, please wait...|
ACST Latest Social Stream
View Full ACST Social Stream
Latest ACST News From Around the Web
Below are the latest news stories about Acasti Pharma Inc that investors may wish to consider to help them evaluate ACST as an investment opportunity.
In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Biotech Penny Stocks to Buy Now. The scintillating pace of technological advancement in the world over the past few decades has transformed the fortunes […]
The trading price of Acasti Pharma Inc. (NASDAQ:ACST) floating higher at last check on Monday, May 17, closing at $0.44, 0.92% higher than its previous close. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Traders who pay close attention to intraday price movement should know that Heres Why Acasti Pharma Inc. (NASDAQ:ACST) is an Attractive Investment Right Now Read More »
Acasti Pharma Inc. announced that, on May 11, 2021, the Company received notice from the Nasdaq Listing Qualifications Department indicating that, based upon the Companys non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550 as of May 10, 2021, the Companys securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UFS, FOE, CHMA, ACST; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
ACASTI PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Acasti Pharma Inc. - ACST
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of Acasti Pharma Inc. (Acasti or the Company) (NasdaqGS: ACST) with Grace Therapeutics Inc., pursuant to which Acasti shareholders will end up owning only approximately 55% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the mer
ACST Price Returns